We also observed a low level expression of ARL2-SNX15, MT-RNR1, and AL591806.3 at 0 weeks during active infection, which were upregulated at 8 weeks after therapy (Figures 4A–C; Table 1). The gene discussed is ARL2; the disease is infection.